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Background: The application of microRNAs (miRNAs) as potential biomarkers and therapy targets has been widely
investigated in many kinds of cancers. The discovery of tumor associated miRNAs in serum of patients supported
the use of plasma/serum miRNAs as noninvasive means of cancer detection. However, the aberrant expression of
miRNAs in bladder cancer patients and their intensive roles and mechanisms in bladder cancer are poorly
understood.
Methods: Taqman probe stem-loop real-time PCR was used to accurately measure the levels of miR-19a in bladder
cancer cell lines, 100 pairs of bladder cancer tissues and the adjacent non-neoplastic tissues and also the plasma
collected from bladder cancer patients and normal controls. miR-19a mimics and inhibitors were transfected into
bladder cancer cells to investigate its role on regulating cell proliferation which was measured by CCK-8 and colony
formation assay. The target of miR-19a was identified by western blot and whether its regulatory role depends on
its target was improved by a rescue experiment with miR-19a mimic and PTEN expression plasmid.
Results: miR-19a was significantly up-regulated in bladder cancer tissues and high-level of miR-19a was correlative
with more aggressive phenotypes of bladder cancer. Meanwhile, gain or loss of function of miR-19a demonstrated
that miR-19a can promote cell growth of bladder cancer cells and the further mechanism studies indicated that its
oncogenic role was dependent on targeting PTEN. Furthermore, investigation of miR-19a expression in the plasma
of bladder cancer patients showed that miR-19a was also increased in plasma of bladder cancer patients which
strongly supported miR-19a could be developed as potential diagnostic marker of bladder cancer.
Conclusions: Our data indicated that miR-19a might act as an oncogenic microRNA in bladder cancer and was
significantly up-regulated in bladder cancer carcinogenesis. The oncogenic role of miR19a in bladder cancer was
dependent on targeting PTEN.
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Bladder cancer is one of the most frequent malignancies
in the world which includes several types of malignancy
arising from the epithelial lining of the urinary bladder.
Chromosomal anomalies, genetic polymorphisms, gen-
etic and epigenetic alterations have been reported to be
included in the tumorigenesis and progression of blad-
der cancer [1]. Recently, the applications of microRNAs
(miRNAs) as potential biomarkers and therapy targets
have been widely investigated in many kinds of cancers.* Correspondence: uroygfeng@sina.com
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molecules functioning in transcriptional and post-tran-
scriptional regulation of gene expression. Recent studies
have documented that miRNAs act as oncogenes or
tumor suppressors in a variety types of cancer, such as
lung, breast, hepatic, and pancreatic cancer [2-7]. Cur-
rently, the aberrant expression of miRNAs has been ob-
served in bladder cancer and several miRNAs have been
reported to play important roles in bladder cancer
tumorigenesis and progression. For example, miR-582-
5p and miR-582-3p are decreased in high-grade bladder
cancer clinical samples, and synthetic miR-582 molecule
can suppress bladder tumor growth and metastasis in
animal model [8]. miR-125b was reported to suppressd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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gene SIRT7 and oncogenic long noncoding RNA
MALAT1 [9]. Down-regulation of miR-99a/100 in blad-
der cancer tissues and their tumor suppressor roles in
bladder cancer cells was also reported [10]. In addition,
some preliminary experiments suggested that miR-23b,
miR-16, miR-124-3p and miR-26a might function as
tumor suppressors in bladder cancer [11-14]. Mean-
while, miR-21 was reported to be up-regulated in high-
grade bladder cancer and can suppress p53 function
[10]. Several oncogenic miRNAs including miR-144,
miR-10b, miR-200c and so on were reported to be in-
volved in bladder cancer progression [15,16]. However,
the aberrant expression of miRNAs in numbers of blad-
der cancer patients and their intensive roles and mecha-
nisms in bladder cancer are poorly understood.
miR-19a/b are recognized to be the most important
miRNAs in the oncomiRs—miR-17-92 cluster. miR-19a/
b has been reported to be deregulated in many kinds of
cancers including acute myeloid leukemia, colorectal
cancer and gastric cancer, and might promote tumor
growth and metastasis [17,18]. High serum levels of
miR-19a are also associated with poor outcome in
metastatic inflammatory breast cancer [19]. The up-
regulation of miR-19a in baldder cancer has been re-
ported by deep sequencing in nine bladder urothelial
carcinoma patients [20]. However, the expression pattern
and the exact role of miR-19a in bladder cancer have
not been elucidated.
In this study, we used Taqman probe stem-loop real-
time PCR to accurately measure the levels of miR-19a in
100 pairs of bladder cancer tissues and the adjacent non-
neoplastic tissues. We found that miR-19a was signifi-
cantly up-regulated in bladder cancer tissues. Enforced ex-
pression of miR-19a can promote the proliferation of
bladder cancer cells, whereas repression of endogenous
miR-19a led to the suppression of cell growth of bladder
cancer cells. In addition, we improved that miR-19a acted
its oncogenic role in bladder cancer partially through tar-
geting PTEN. Furthermore, investigation of miR-19a ex-
pression in the plasma of bladder cancer patients showed
that miR-19a was also increased in plasma of bladder can-
cer patients which strongly supported miR-19a could be
developed as potential diagnostic marker of bladder
cancer.
Methods
Cell culture and transfections
The human bladder cancer cell lines (J82, HT1376, RT4,
T24 and TCCSUP) and immortalized human bladder epi-
thelium (HCV29 and HU609) cells were propagated in
DMEM (Invitrogen) supplemented with 10% FCS at 37°C
in 5% CO2 cell culture incubator. miR-19a mimics, inhibi-
tors and scramble control were obtained from Dharmaconand transfected with DharmFECT1 (Dharmacon) at a final
concentration of 50 nM. The plasmid expressing PTEN
was obtained from Origene (SC119965) and co-transfected
with miR-19a mimics at 2 μg/ml.
Patients and specimens
The human clinical samples were collected from surgical
specimens from 100 patients with bladder cancer at
Suining Central Hospital. The corresponding adjacent
non-neoplastic tissues from the macroscopic tumor mar-
gin were isolated at the same time and used as controls.
All samples were immediately snapped frozen in liquid
nitrogen and stored at −80°C until RNA extraction.
Whole blood samples were prospectively collected from
bladder cancer patients and control patients without uro-
logic malignancies. Whole blood (5–8 ml) was collected in
an ethylene diamine tetracetic acid (EDTA) tube. The
sample was centrifuged twice at 4°C. Plasma (supernatant
after second centrifugation) was then stored at −80°C. The
Clinical Research Ethics Committee of Suining Central
Hospital approved the research protocols and written in-
formed consent was obtained from the participants.
RNA extraction, cDNA synthesis, and real-time PCR assays
Total RNA was extracted from tissues and cells using
Trizol reagent (Invitrogen, CA, USA) according to the
manufacturer’s instructions. Total RNA of plasma was
isolated using a commercially available kit (mirVana;
miRNA Isolation Kit, Applied Biosystems, Carlsbad, CA)
according to the manufacturer’s protocol. RNA was
quantified and cDNA was synthesized by M-MLV re-
verse transcriptase (Invitrogen) from 2 μg of total RNA.
A stem-loop RT primer was used for the reverse tran-
scription. Quantitative RT-PCR was performed in a Bio-
Rad CFX96 real-time PCR System (Bio-Rad, CA, USA)
using TaqMan probes (Applied Biosystems, Foster City,
CA, USA) according to the manufacturer’ s instructions.
The PCR conditions were as follows: 95°C for 30 s,
followed by 40 cycles of 95°C for 5 s and 60°C for 34 s.
The data were normalized using the endogenous U6
snRNA. The 2-ΔΔCT method was used in the analysis
of PCR data. Primer sequences are presented in Table 1.
Cell proliferation assay and colony formation assay
To measure the effect of miRNA mimics or FSCN1
siRNA on cell proliferation, cells were incubated in 10%
CCK-8 (DOJINDO) diluted in normal culture media at
37°C until visual color conversion appears. Proliferation
rates were determined at day 1, 2, 3, 4 post-transfection,
and quantification was done on a microtiter plate reader
(Spectra Rainbow, Tecan) according to the manufactur-
er's protocol. Meanwhile, the mimic-transfected cells
were trypsinized and replated at 200 cells per well in 6-
well plates, cultured for 7 days, then fixed with methanol
Table 1 Sequence of primers used in qRT-PCR
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15 min.
Western blotting
Whole-cell lysate or nuclear extract was subjected to
Western blot analysis as described previously [21]. The
following antibodies were used for Western blot:
GAPDH (10494-1-AP, Proteintech), PTEN (22034-1-AP,
Proteintech).
Statistics
The statistical analyses for miR-19a expression in clinical
samples, correlation of miR-19a expression with patients’
clinicopathological variables were conducted using the
Bonferroni multiple-comparison test. The other statistical
analyses were evaluated by independent samples T test
(two-tailed). P ≤ 0.05 was considered statistically significant.
Results
miR-19a is up-regulated in bladder cancer cells
To analyze the expression of miR-19a in bladder cancer,
q-PCR using Taqman probes was conducted to measure
the levels of miR-19a. We firstly examined the expres-
sion of mature miR-19a in immortalized human bladder
epithelium (HCV29 and HU609) cells and five human
bladder cancer cell lines (J82, HT1376, RT4, T24 and
TCCSUP). The expression level of miR-19a in bladder
cancer cell lines was significant higher than that in the
normal bladder epithelium cells. Expression level of
miR-19a in RT4 was a little lower than that in the four
other bladder cancer cell lines (Figure 1A). These data
demonstrated that the up-regulation of miR-19a might
be relevant to the genesis and development of bladder
cancer.
miR-19a is up-regulated in bladder cancer tissues com-
pared with the corresponding adjacent non- neoplastic
tissues
To further analyze the expression of miR-19a in patients
with bladder cancer, we measured the levels of miR-19a
in 100 pairs of bladder cancer tissues (C) and theadjacent non-neoplastic tissues (N). The results of PCR
showed that 55/100 (55%) of cases had increased levels
of miR-19a in bladder cancer tissues compared with the
corresponding non-neoplastic tissues when the cutoff
was set up as 1.5 (Figure 1B). There were 20/100 (20%)
of cases had reduced levels of miR-19a in bladder cancer
tissues compared with the adjacent non-neoplastic tis-
sues, 25/100 (25%) of cases in whom the expression of
miR-19a was slightly changed in bladder cancer tissues.
The results also showed that the average expression of
miR-19a in bladder cancer samples was significantly
higher than that in the adjacent non-neoplastic tissues
(p < 0.05) (Figure 1C).
To further investigate the correlation between the ex-
pression of miR-19a and the clinicopathological charac-
teristics, the relative expression of miR-19a in 100 pairs
of bladder cancer tissues and adjacent normal tissues
were statistically analyzed. The clinicopathological fea-
tures of bladder cancer patients were summarized in
Table 2. Correlation analysis showed that high-level ex-
pression of miR-19a in bladder cancer was significantly
associated with a more aggressive tumor phenotype
(Figure 1D). The data also demonstrated that the ex-
pression level of miR-19a had no correlation with age,
gender and histological type. Collectively, the data indi-
cated that miR-19a was significantly up-regulated in
tumor tissues and might play important roles in bladder
carcinogenesis as an oncogenic miRNA.
Enforced expression of miR-19a promotes bladder cancer
cell growth and colony formation
To investigate the role of miR-19a in bladder carcino-
genesis, we overexpressed miR-19a in the two bladder
cancer cell lines RT4 and TCCSUP which had lower ex-
pression of miR-19a than the other bladder cancer cell
lines. Successful overexpression of miR-19a in the two
bladder cancer cell lines was confirmed by q-PCR. miR-
19a was overexpressed about 28 folds and 15 folds than
the scramble control or untreated RT4 and TCCSUP
cells respectively (Figure 2A, C). Consistent with its up-
regulation in bladder cancer, the overexpression of miR-
Figure 1 miR-19a is significantly up-regulated in bladder cancer cell lines and in bladder cancer tissues. (A) The expression level of
miR-19a in two immortalized human bladder epithelium cells (HCV29 and HU609) and five bladder cancer cell lines (J82, HT1376, RT4, T24 and
TCCSUP). Data are shown as mean + s.d. (n = 3); * indicates P-value < 0.05; ** indicates P-value < 0.01; *** indicates P-value < 0.001. (B) The relative
expression of miR-19a in 100 pairs of bladder cancer (C) and adjacent non-neoplastic tissues (N). (C) Normalized expression of miR-19a in 100
pairs of bladder cancer and adjacent normal tissues. (D) The correlation of miR-19a expression with tumor grades of bladder cancer tissues.
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cancer cell proliferation significantly as demonstrated by
CCK-8 assay. The scramble control had no effect on
cell proliferation compared with the untreated cells
(Figure 2B, D). We also detected the effect of miR-19a
on the colony formation ability of bladder cancer cells.
The mimic-transfected cells were replated at low density
and maintained for 7 days. The overexpression of miR-
19a significantly increased the colony number of RT4
and TCCSUP cells, whereas the scramble control had
little effect on the colony number compared with the
untreated cells (Figure 2E, F). The results proved that
miR-19a acted as an oncogenic miRNA in bladder can-
cer and the up-regulation of miR-19a in bladder tissues
would lead to unlimited cell proliferation.Attenuated expression of miR-19a in bladder cancer cells
can inhibit cell growth and colony formation
To further confirm the oncogenic role of miR-19a in
bladder carcinogenesis, we suppressed the expression of
miR-19a in the two bladder cancer cell lines J82 and
HT1376 which had higher expression of miR-19a than
the other bladder cancer cell lines. Successful repression
of miR-19a in the two bladder cancer cell lines was con-
firmed by q-PCR (Figure 3A, C). As demonstrated by
CCK-8 growth assays, repression of miR-19a reduced
cell proliferation in both the two cell lines, whereas the
scramble control had no effect on cell proliferation com-
pared with the untreated cells (Figure 3B, D). As demon-
strated by the colony formation assay, repression of
miR-19a also significantly decreased the colony number
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had little effect on the colony number compared with
the untreated cells (Figure 3E, F). The results proved
that miR-19a might act as an oncogenic miRNA in blad-
der cancer again.
miR-19a plays its oncogenic role in bladder cancer
through targeting PTEN
We further dissected the mechanism of miR-19a func-
tioning as an oncogenic miRNA in bladder cancer.
PTEN has been verified as a functional target of miR-
19a/b in regulating multidrug resistance in gastric cancer
and breast cancer. PTEN acts as a tumor suppressor
gene through its phosphatase protein product in a var-
iety of cancers. However, it was still unknown whether
miR-19a played its oncogenic roles through targeting
PTEN in bladder cancer. So we detected the PTEN pro-
tein level in RT4 and TCCSUP cells transfected with
miR-19a mimics and also in J82 and HT1376 cells trans-
fected with miR-19a inhibitors. As expected, the PTEN
protein level was decreased evidently in presence of
miR-19a mimics compared to scramble control in bothof RT4 and TCCSUP cells. Conversely, PTEN was in-
creased in presence of miR-19a inhibitors compared to
scramble control in both of J82 and HT1376 cells
(Figure 4A, B). These results indicated that miR-19a
down-regulated PTEN protein in bladder cancer cells.
To further investigate whether miR-19a functions
through targeting PTEN in bladder cancer cells, we
employed a rescue experiment with miR-19a mimics and
PTEN expression plasmid in RT4 and TCCSUP cells. A
decrease in PTEN after treatment with miR-19a mimics
confirmed the regulatory role of miR-19a on the expres-
sion of the target. The addition of PTEN expression
plasmid led to further up-regulation of PTEN based on
the previously described down-regulation in both of RT4
and TCCSUP cells (Figure 4C, D). Consistent with the
restored expression of PTEN protein, promotion of cell
growth by miR-19a mimics was rescued by the addition
of PTEN expression plasmid (Figure 4C, D). These data
confirmed the regulatory role of miR-19a in bladder can-
cer cells was through targeting PTEN.
miR-19a is also up-regulated in the plasma of patients
with bladder cancer
To explore the diagnostic potential of miR-19a in blad-
der cancer, we detected the expression of miR-19a in the
plasma of 50 patients with bladder cancer and 50 healthy
individuals. The data demonstrated that the average level
of miR-19a in the bladder cancer patients was signifi-
cantly higher than that in the healthy individuals which
was consistent with its up-regulation in bladder cancer
tissues (Figure 5A). The results suggested that miR-19a
could be released from the bladder epithelium to the
blood and increased miR-19a in the bladder cancer tis-
sues caused its up-regulation in the plasma. The high-
level expression of miR-19a in the plasma of bladder
cancer patients was also significantly associated with a
more aggressive tumor phenotype (Figure 5B). The in-
creased expression of miR-19a in the plasma of bladder
cancer patients suggested that miR-19a can be developed
as a potential diagnostic marker which can be combined
with other miRNAs’ expression to detect bladder cancer.
Discussion
The up-regulated expression of miR-17–92 cluster has
been reported in a variety of cancers including multiple
myeloma, leukemia, colorectal cancer and breast cancer
[22-24]. The miRNA cluster produces a single primary
transcript yielding the six mature miRNAs: miR-17, miR-
18a, miR-19a, miR-20a, miR-19b, and miR-92a. miR-19
has been identified as the key member responsible for the
oncogenic activity [25,26]. However, the role of miR-19 in
bladder cancer remains unknown. In this study, we inves-
tigated the expression of miR-19a in a great deal of pa-
tients with bladder cancer and dissected the roles and
Figure 2 Enforced expression of miR-19a promotes bladder cancer cell growth and colony formation. (A) Overexpression of miR-19a in RT4
cells was confirmed by qRT-PCR. (B) The cell growth of RT4 cells at 0, 1, 2, 3, 4 days post transfection which was detected by CCK-8 assay.
(C) Overexpression of miR-19a in TCCSUP cells was confirmed by qRT-PCR. (D) The cell growth of TCCSUP cells at 0, 1, 2, 3, 4 days post transfection
which was detected by CCK-8 assay. (E) The colony number of RT4 cells per well in 6-well plates cultured for 7 days. (F) The colony number of
TCCSUP cells per well in 6-well plates cultured for 7 days. Data are shown as mean + s.d. (n = 3); * indicates P-value < 0.05; ** indicates P-value < 0.01;
*** indicates P-value < 0.001.
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esis. We found that miR-19a was significantly up-
regulated in bladder cancer tissues and the high
expression of miR-19a was associated with the more
aggressive phenotypes of bladder cancer. Gain or loss
of function of miR-19a in bladder cancer cells also in-
dicated that miR-19a can promote cell growth which
was consistent with its role in other cancer types. Theimportant role of miR-19a in regulating bladder cancer
cell invasion, migration and in vivo carcinogenesis
needs to be further confirmed. In case anti-miRs of
miR-19a can suppress tumor growth in vivo signifi-
cantly, miR-19a can be further developed as new target
for bladder cancer therapy as miRNAs has advantages
of being small and easy to delivery, safer than other
gene therapy methods [27,28].
Figure 3 Attenuated expression of miR-19a in bladder cancer cells can inhibit cell growth and colony formation. (A) Repression of
miR-19a in J82 cells was confirmed by qRT-PCR. (B) The cell growth of J82 cells at 0, 1, 2, 3, 4 days post transfection which was detected by CCK-8
assay. (C) Repression of miR-19a in HT1376 cells was confirmed by qRT-PCR. (D) The cell growth of HT1376 cells at 0, 1, 2, 3, 4 days post transfection
which was detected by CCK-8 assay. (E) The colony number of J82 cells per well in 6-well plates cultured for 7 days. (F) The colony number of HT1376
cells per well in 6-well plates cultured for 7 days. Data are shown as mean + s.d. (n = 3); * indicates P-value < 0.05; ** indicates P-value < 0.01;
*** indicates P-value < 0.001.
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functioned as an oncogenic miRNA in bladder cancer,
we analyzed the relationship of miR-19a and PTEN in
bladder cancer and found that the regulatory role of
miR-19a in bladder cancer cells was dependent on tar-
geting PTEN. PTEN is identified as a tumor suppressor
that is mutated in a large number of cancers at high
frequency. It negatively regulates intracellular levels
of phosphatidylinositol-3,4,5-trisphosphate in cells andfunctions as a tumor suppressor by negatively regulating
AKT/PKB signaling pathway [29-31]. AKT/PKB signal-
ing pathways answer to growth factors and other extra-
cellular stimuli to regulate several cellular functions
including nutrient metabolism, cell growth, apoptosis
and survival. miR-19a may repress the expression of
PTEN which further lead to the unlimited cell prolifera-
tion of bladder cancer cells. The correlation of expres-
sion level of miR-19a and PTEN in patients with bladder
Figure 4 miR-19a plays its oncogenic role in bladder cancer through targeting PTEN. (A) Western blot analysis of PTEN expression in RT4
and TCCSUP cells transfected with scramble control or miR-19a mimics. (B) Western blot analysis of PTEN expression in J82 and HT1376 cells
transfected with scramble control or miR-19a inhibitors. (C) Western blot of PTEN expression and CCK-8 analysis of cell growth of RT4 cells
transfected with miR-19a mimic and PTEN expression plasmid. (D) Western blot of PTEN expression and CCK-8 analysis of cell growth of TCCSUP
cells transfected with miR-19a mimic and PTEN expression plasmid.
Figure 5 Expression of miR-19a in the plasma of patients with bladder cancer. (A) Normalized expression of miR-19a in the plasma of 50
patients with bladder cancer and 50 healthy individuals. (B) Correlation of miR-19a expression in the plasma with the tumor grades of
bladder cancer.
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was a direct target of miR-19a in bladder cancer.
Earlier studies discovered that extracellular miRNAs cir-
culated in the bloodstream and the circulating miRNAs
were remarkably stable. Detection of elevated levels of
tumor associated miRNAs in serum of patients with dif-
fuse large B-cell lymphoma [32] leads to widely investiga-
tion of circulating miRNAs in many human cancers,
including breast cancer [33], lung cancer [34], prostate
cancer [35], and renal cell carcinoma [36] and so on. The
expression profile of miRNAs in serum/plasma of the pa-
tients with bladder cancer was also investigated and some
important circulating miRNAs in bladder cancer had been
identified [37,38]. These studies support the use of serum/
plasma miRNAs as noninvasive means of bladder cancer
detection. Serum miR-19a expression has been reported
to correlate with worse prognosis of patients with non-
small cell lung cancer [39]. We detected the level of miR-
19a in plasma of patients with bladder cancer and found
that miR-19a was also increased which was consistent
with its high level in the cancer tissues. The up-regulation
of miR-19a in the plasma might origin from the tumor
cells which needs to be improved further. MiRNAs can be
detected easily in small amount samples and are stable
against degradation and can be detectable in bodily fluids
including serum, plasma, saliva, urine and tears [40,41].
The innate properties of miRNAs make them attractive as
potential biomarkers. So miR-19a can be developed as a
new diagnostic marker for bladder cancer detection. Fur-
ther analysis of the correlation of miR-19a expression level
with clinical outcome will offer important information
about the relationship of miR-19a levels with the clinical
diagnosis, therapy and outcome, which will be useful for
individualized therapies. In consideration of the possible
secretion of miR-19a from the tumor cells to the plasma,
the level of miR-19a in urine samples of the patients will
be examined. Voided urine can be noninvasively obtained,
be designed not only for diagnosis, but also for monitoring
disease recurrence and response to therapy [42,43]. So de-
velopment of miR-19a as a novel urinary biomarker for
bladder cancer will be urgently required for early detec-
tion of cancer and individualized therapies.Conclusion
In summary, we determined the high expression of miR-
19a in the cancer tissues and plasma of patients with blad-
der cancer and also indicated the oncogenic roles of
miR19a in bladder cancer which was dependent on target-
ing PTEN. Our data provided the potential diagnostic and
therapeutic roles of miR-19a in bladder cancer firstly.Competing interests
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